New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method
Yıl: 2021 Cilt: 49 Sayı: 5 Sayfa Aralığı: 345 - 352 Metin Dili: İngilizce DOI: 10.5543/tkda.2021.40652 İndeks Tarihi: 29-01-2022
New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method
Öz: -
Anahtar Kelime: Böbrek Hastalığı olan AF Olgularında non-vitamin K antagonisti oral antikoagülanların kullanımı (NOACURE-AF) - Neredeyiz?: Delphi yöntemi kullanan bir uzman uzlaşı raporu
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
- 1. Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and mechanisms of uremia-related cardiovascular disease. Circulation 2016;133:518-36. [Crossref]
- 2. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021;42:373-498. [Crossref]
- 3. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-106. [Crossref]
- 4. Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 2015;66:677-88. [Crossref]
- 5. Wang TK, Sathananthan J, Marshall M, Kerr A, Hood C. Relationships between anticoagulation, risk scores and adverse outcomes in dialysis patients with atrial fibrillation. Heart Lung Circ 2016;25:243-9. [Crossref]
- 6. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 2014;11:1752-9. [Crossref]
- 7. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35. [Crossref]
- 8. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-82. [Crossref]
- 9. Sood MM, Rigatto C, Bueti J, Lang C, Miller L, Ponnam Palam A, et al. Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transplant 2009;24:3162- 7. [Crossref]
- 10. Galloway PA, El-Damanawi R, Bardsley V, Pritchard NR, Fry AC, Ojha SK, et al. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease. Nephron 2015;129:197-201. [Crossref]
- 11. Pokorney SD. RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF). Presentation at the American Heart Association Annual Scientific Sessions (AHA 2019), Philadelphia, PA, November 16, 2019.
- 12. Hu A, Niu J, Winkelmayer WC. Oral anticoagulation in patients with end-stage kidney disease on dialysis and atrial fibrillation. Semin Nephrol 2018;38:618-28. [Crossref]
- 13. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017;28:2241-8. [Crossref]
- 14. Koretsune Y, Yamashita T, Kimura T, Fukuzawa M, Abe K, Yasaka M. Shortterm safety and plasma concentrations of edoxaban in Japanese patients with non-valvular atrial fibrillation and severe renal impairment. Circ J 2015;79:1486-95. [Crossref]
- 15. De Vriese AS, Caluwe R, Bailleul E, De Bacquer D, Borrey D, Van Vlem B, et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015;66:91-8. [Crossref]
- 16. Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138:1519-29. [Crossref]
- 17. Diamond IR, Grant RC, Feldman BM, Pencharz PB, Ling SC, Moore AM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 2014;67:401-9. [Crossref]
- 18. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 2013;34:3572-9. [Crossref]
- 19. Roldan V, Marin F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2 VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109:956-60. [Crossref]
- 20. Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J 2013;34:3572-9. [Crossref]
- 21. Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127:224-32. [Crossref]
- 22. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. Circulation 2019;140:e125-51. [Crossref]
- 23. Basaran O, Filiz Basaran N, Cekic EG, Altun I, Dogan V, Mert GO, et al. PRescriptiOn pattERns of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study). Clin Appl Thromb Hemost 2017;23:384-91. [Crossref]
- 24. Kuo CC, Kuo HW, Lee IM, Lee CT, Yang CY. The risk of upper gastrointestinal bleeding in patients treated with hemodialysis: a population-based cohort study. BMC Nephrol 2013;14:15. [Crossref]
- 25. Shen JI, Montez-Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 2015;66:677-88. [Crossref]
- 26. Phelan PJ, O’Kelly P, Holian J, Walshe JJ, Delany C, Slaby J, et al. Warfarin use in hemodialysis patients: what is the risk? Clin Nephrol 2011;75:204-11. [Crossref]
- 27. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35. [Crossref]
- 28. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-33. [Crossref]
- 29. Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 2017;184:37-46. [Crossref]
- 30. Tan J, Liu S, Segal JB, Alexander GC, McAdams-DeMarco M. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol 2016;17:157. [Crossref]
- 31. Harel Z, Chertow GM, Shah PS, Harel S, Dorian P, Yan AT, et al. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis. Can J Cardiol 2017;33:737-46. [Crossref]
- 32. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011;80:17-28. [Crossref]
- 33. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 2016;149:951-9. [Crossref]
- 34. Brodsky SV. Anticoagulants and acute kidney injury: clinical and pathology considerations. Kidney Res Clin Pract 2014;33:174-80. [Crossref]
- 35. Yao X, Tangri N, Gersh BJ, Sangaralingham LR , Shah ND, Nath KA. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2017;70:2621-32. [Crossref]
- 36. Yang F, Hellyer JA, Than C, Ullal AJ, Kaiser DW, Heidenreich PA. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart 2017;103:818-26. [Crossref]
- 37. Hasbal NB, Koç Y, Sakacı T, Sevinç M, Uçar ZA, Şahutoğlu T, et al. Prevalence and characteristics of atrial fibrillation in Turkish patients undergoing hemodialysis. Turkish J Nephrol 2020;29:215-20. [Crossref]
- 38. Van Zyl M, Abdullah HM, Noseworthy PA, Siontis KC. Stroke prophylaxis in patients with atrial fibrillation and end-stage renal disease. J Clin Med 2020;9:123. [Crossref]
- 39. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330- 93. [Crossref]
- 40. De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 2021;32:1474-83. [Crossref]
| APA | ARICI M, Ecder T, Erdinler I, Ok E, arican ozluk o, TURK U, Alioglu E (2021). New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. , 345 - 352. 10.5543/tkda.2021.40652 |
| Chicago | ARICI Mustafa,Ecder Tevfik,Erdinler Izzet Celal,Ok Ercan,arican ozluk ozlem,TURK UGUR ONSEL,Alioglu Emin New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. (2021): 345 - 352. 10.5543/tkda.2021.40652 |
| MLA | ARICI Mustafa,Ecder Tevfik,Erdinler Izzet Celal,Ok Ercan,arican ozluk ozlem,TURK UGUR ONSEL,Alioglu Emin New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. , 2021, ss.345 - 352. 10.5543/tkda.2021.40652 |
| AMA | ARICI M,Ecder T,Erdinler I,Ok E,arican ozluk o,TURK U,Alioglu E New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. . 2021; 345 - 352. 10.5543/tkda.2021.40652 |
| Vancouver | ARICI M,Ecder T,Erdinler I,Ok E,arican ozluk o,TURK U,Alioglu E New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. . 2021; 345 - 352. 10.5543/tkda.2021.40652 |
| IEEE | ARICI M,Ecder T,Erdinler I,Ok E,arican ozluk o,TURK U,Alioglu E "New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method." , ss.345 - 352, 2021. 10.5543/tkda.2021.40652 |
| ISNAD | ARICI, Mustafa vd. "New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method". (2021), 345-352. https://doi.org/10.5543/tkda.2021.40652 |
| APA | ARICI M, Ecder T, Erdinler I, Ok E, arican ozluk o, TURK U, Alioglu E (2021). New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. Türk Kardiyoloji Derneği Arşivi, 49(5), 345 - 352. 10.5543/tkda.2021.40652 |
| Chicago | ARICI Mustafa,Ecder Tevfik,Erdinler Izzet Celal,Ok Ercan,arican ozluk ozlem,TURK UGUR ONSEL,Alioglu Emin New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. Türk Kardiyoloji Derneği Arşivi 49, no.5 (2021): 345 - 352. 10.5543/tkda.2021.40652 |
| MLA | ARICI Mustafa,Ecder Tevfik,Erdinler Izzet Celal,Ok Ercan,arican ozluk ozlem,TURK UGUR ONSEL,Alioglu Emin New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. Türk Kardiyoloji Derneği Arşivi, vol.49, no.5, 2021, ss.345 - 352. 10.5543/tkda.2021.40652 |
| AMA | ARICI M,Ecder T,Erdinler I,Ok E,arican ozluk o,TURK U,Alioglu E New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. Türk Kardiyoloji Derneği Arşivi. 2021; 49(5): 345 - 352. 10.5543/tkda.2021.40652 |
| Vancouver | ARICI M,Ecder T,Erdinler I,Ok E,arican ozluk o,TURK U,Alioglu E New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method. Türk Kardiyoloji Derneği Arşivi. 2021; 49(5): 345 - 352. 10.5543/tkda.2021.40652 |
| IEEE | ARICI M,Ecder T,Erdinler I,Ok E,arican ozluk o,TURK U,Alioglu E "New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method." Türk Kardiyoloji Derneği Arşivi, 49, ss.345 - 352, 2021. 10.5543/tkda.2021.40652 |
| ISNAD | ARICI, Mustafa vd. "New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) - Where do we stand?: An expert consensus view using the Delphi method". Türk Kardiyoloji Derneği Arşivi 49/5 (2021), 345-352. https://doi.org/10.5543/tkda.2021.40652 |
